/

ARDS

Aridis Pharmaceuticals Inc.Closed

0.0001000.00 0.00%USD

OTC Markets OTCPK · as of Oct 12, 16:00 ET · 15m delay

Open

0.001450

Prev close

0.000100

Day range

0.0014500.001450

52-week range

0.0001000.0500

Volume

100.00×

Mkt cap

4.46K

P/E ttm

—

Fwd P/E

-0.00

EPS ttm

-0.1600

Div yield

0.00%

Earnings

—

From 52w high

−99.80%

Price Chart

Yahoo Finance · delayed

ARDSOct 12, 2026O 0.0001H 0.0001L 0.0001C 0.00010.0000 (0.00%)Vol 600

SMA 500.0001
SMA 2000.0004

1Y change −95.65% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ARDS Aridis Pharmaceuticals Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: 0.00%
1 month: 0.00%
3 months: 0.00%
6 months: −50.00%
Year to date: −93.33%
1 year: −95.65%

Valuation & ownership

Market cap: 4.46K
Enterprise value: 4.81M
P/E (ttm): —
Forward P/E: -0.00
PEG ratio: —
Price / book: —
Price / sales (ttm): 0.00
EV / EBITDA: -13.86
EPS (ttm): -0.1600
EPS (forward): -0.0900
Beta (5y monthly): 3431.53
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 44.57M
Float: 40.31M
Short % of float: 8.23%
Short ratio (days): 1.52
Held by insiders: 0.00%
Held by institutions: 11.44%
Avg volume (3m): 4.64K
50-day average: 0.000100
200-day average: 0.000441
52-week change: −95.65%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 41.4
vs 50-day SMA: 0.00%
vs 200-day SMA: −75.87%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 2.56%
Realised vol (20d, ann.): 0.0%
From 52-week high: −99.80%
From 52-week low: 0.00%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 22.36M
Revenue growth (yoy): +4.50%
Earnings growth (yoy): —
Gross margin: 23.28%
Operating margin: -208.39%
Profit margin: -5.11%

DES

About Aridis Pharmaceuticals Inc.

Yahoo Finance profile

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 37
Headquarters: Los Gatos, CA, United States
Website: aridispharma.com
Officers: Dr. Eric J. Patzer Ph.D. Founder & Executive Chairman

SEAS

Seasonality · ARDS

2018–2026 · monthly returns

Strongest month Sep +137.51%Weakest month Oct −26.08%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-86.7	800.0	-88.9	0.0	0.0	-50.0	0.0	0.0	0.0	0.0			−93.3%
2025	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1200.0	-84.6	0.0	650.0	+1400.0%
2024	0.1	10.0	1.0	-23.1	4.2	-20.3	-98.0	0.0	0.0	-80.0	-50.0	0.0	−99.9%
2023	-43.2	-15.8	-44.3	-42.8	121.0	-44.7	-2.2	-46.6	-11.0	-7.7	-14.1	-13.5	−94.1%
2022	-22.3	10.5	-12.0	-29.0	-8.0	-4.3	124.5	-40.9	-36.3	11.8	-12.5	29.7	−49.4%
2021	15.6	-10.1	-6.5	5.6	-7.2	28.0	-32.6	-19.4	-8.5	-4.9	-35.4	3.1	−61.6%
2020	55.3	-2.5	-14.4	10.9	8.5	-4.5	5.6	0.0	1.1	-12.6	10.5	-11.3	+36.4%
2019	-24.6	3.8	31.3	-22.7	-1.2	16.9	-14.5	34.3	-42.4	-24.9	8.8	-19.1	−59.9%
2018									-2.9	-5.8	-13.8	4.6	−17.5%

ARDS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ARDS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Aridis Pharmaceuticals Inc.

Seasonality · ARDS

Insider Activity · ARDS

Congress Trades · ARDS

Investors Holding ARDS

Investors Holding ARDS

Congress Trades · ARDS

Insider Activity · ARDS

Seasonality · ARDS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Aridis Pharmaceuticals Inc.

Earnings & Dividends

News